Literature DB >> 18930112

Complex actions of thyroid hormone receptor antagonist NH-3 on gene promoters in different cell lines.

Vanya Shah1, Phuong Nguyen, Ngoc-Ha Nguyen, Marie Togashi, Thomas S Scanlan, John D Baxter, Paul Webb.   

Abstract

It is desirable to obtain new antagonists for thyroid hormone receptors (TRs) and other nuclear receptors (NRs). We previously used X-ray structural models of TR ligand binding domains (LBDs) to design compounds, such as NH-3, that impair coactivator binding to activation function 2 (AF-2) and block thyroid hormone (triiodothyronine, T(3)) actions. However, TRs bind DNA and are transcriptionally active without ligand. Thus, NH-3 could modulate TR activity via effects on other coregulator interaction surfaces, such as activation function (AF-1) and corepressor binding sites. Here, we find that NH-3 blocks TR-LBD interactions with coactivators and corepressors and also inhibits activities of AF-1 and AF-2 in transfections. While NH-3 lacks detectable agonist activity at T(3)-activated genes in GC pituitary cells it nevertheless activates spot 14 (S14) in HTC liver cells with the latter effect accompanied by enhanced histone H4 acetylation and coactivator recruitment at the S14 promoter. Surprisingly, T(3) promotes corepressor recruitment to target promoters. NH-3 effects vary; we observe transient recruitment of N-CoR to S14 in GC cells and dismissal and rebinding of N-CoR to the same promoter in HTC cells. We propose that NH-3 will generally behave as an antagonist by blocking AF-1 and AF-2 but that complex effects on coregulator recruitment may result in partial/mixed agonist effects that are independent of blockade of T(3) binding in some contexts. These properties could ultimately be utilized in drug design and development of new selective TR modulators.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930112      PMCID: PMC4180716          DOI: 10.1016/j.mce.2008.09.016

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  58 in total

1.  Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.

Authors:  Ngoc-Ha Nguyen; James W Apriletti; Suzana T Cunha Lima; Paul Webb; John D Baxter; Thomas S Scanlan
Journal:  J Med Chem       Date:  2002-07-18       Impact factor: 7.446

2.  Thyroid hormone-regulated target genes have distinct patterns of coactivator recruitment and histone acetylation.

Authors:  Ying Liu; Xianmin Xia; Joseph D Fondell; Paul M Yen
Journal:  Mol Endocrinol       Date:  2005-10-27

3.  A dominant-negative thyroid hormone receptor blocks amphibian metamorphosis by retaining corepressors at target genes.

Authors:  Daniel R Buchholz; Shao-Chung Victor Hsia; Liezhen Fu; Yun-Bo Shi
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

4.  An LXXLL motif in nuclear receptor corepressor mediates ligand-induced repression of the thyroid stimulating hormone-beta gene.

Authors:  Kristina Loinder; Mats Söderström
Journal:  J Steroid Biochem Mol Biol       Date:  2005-10-10       Impact factor: 4.292

5.  Thyroid hormone response element organization dictates the composition of active receptor.

Authors:  Lara F R Velasco; Marie Togashi; Paul G Walfish; Rutinéia P Pessanha; Fanny N Moura; Gustavo B Barra; Phuong Nguyen; Rachelle Rebong; Chaoshen Yuan; Luiz A Simeoni; Ralff C J Ribeiro; John D Baxter; Paul Webb; Francisco A R Neves
Journal:  J Biol Chem       Date:  2007-02-20       Impact factor: 5.157

6.  Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors.

Authors:  W Feng; R C Ribeiro; R L Wagner; H Nguyen; J W Apriletti; R J Fletterick; J D Baxter; P J Kushner; B L West
Journal:  Science       Date:  1998-06-12       Impact factor: 47.728

7.  Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins.

Authors:  Kelly J Higgins; Shengxi Liu; Maen Abdelrahim; Kathryn Vanderlaag; Xinyi Liu; Weston Porter; Richard Metz; Stephen Safe
Journal:  Mol Endocrinol       Date:  2007-11-15

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

9.  Pharmacological profile of the thyroid hormone receptor antagonist NH3 in rats.

Authors:  Gary J Grover; Celeste Dunn; Ngoc-Ha Nguyen; Jamie Boulet; Gao Dong; Jason Domogauer; Peter Barbounis; Thomas S Scanlan
Journal:  J Pharmacol Exp Ther       Date:  2007-04-17       Impact factor: 4.030

10.  A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor.

Authors:  Florian Blaschke; Yasunori Takata; Evren Caglayan; Alan Collins; Peter Tontonoz; Willa A Hsueh; Rajendra K Tangirala
Journal:  Circ Res       Date:  2006-11-16       Impact factor: 17.367

View more
  8 in total

1.  Similarities and differences between two modes of antagonism of the thyroid hormone receptor.

Authors:  Prabodh Sadana; Jong Yeon Hwang; Ramy R Attia; Leggy A Arnold; Geoffrey Neale; R Kiplin Guy
Journal:  ACS Chem Biol       Date:  2011-08-15       Impact factor: 5.100

2.  Inhibition of thyroid hormone receptor locally in the retina is a therapeutic strategy for retinal degeneration.

Authors:  Hongwei Ma; Fan Yang; Michael R Butler; Joshua Belcher; T Michael Redmond; Andrew T Placzek; Thomas S Scanlan; Xi-Qin Ding
Journal:  FASEB J       Date:  2017-04-20       Impact factor: 5.191

3.  Synthesis and evaluation of methylsulfonylnitrobenzamides (MSNBAs) as inhibitors of the thyroid hormone receptor-coactivator interaction.

Authors:  Jong Yeon Hwang; Ramy R Attia; Angela K Carrillo; Michele C Connelly; R Kiplin Guy
Journal:  Bioorg Med Chem Lett       Date:  2013-01-08       Impact factor: 2.823

4.  Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange.

Authors:  A C M Figueira; D M Saidemberg; P C T Souza; L Martínez; T S Scanlan; J D Baxter; M S Skaf; M S Palma; P Webb; I Polikarpov
Journal:  Mol Endocrinol       Date:  2010-11-24

5.  Methylsulfonylnitrobenzoates, a new class of irreversible inhibitors of the interaction of the thyroid hormone receptor and its obligate coactivators that functionally antagonizes thyroid hormone.

Authors:  Jong Yeon Hwang; Wenwei Huang; Leggy A Arnold; Ruili Huang; Ramy R Attia; Michele Connelly; Jennifer Wichterman; Fangyi Zhu; Indre Augustinaite; Christopher P Austin; James Inglese; Ronald L Johnson; R Kiplin Guy
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

6.  Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors.

Authors:  Jong Yeon Hwang; Ramy R Attia; Fangyi Zhu; Lei Yang; Andrew Lemoff; Cynthia Jeffries; Michele C Connelly; R Kiplin Guy
Journal:  J Med Chem       Date:  2012-02-23       Impact factor: 7.446

7.  Identification of CCR4 and other essential thyroid hormone receptor co-activators by modified yeast synthetic genetic array analysis.

Authors:  Manjapra Govindan; Xianwang Meng; Clyde L Denis; Paul Webb; John D Baxter; Paul G Walfish
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-10       Impact factor: 11.205

8.  American Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models.

Authors:  Antonio C Bianco; Grant Anderson; Douglas Forrest; Valerie Anne Galton; Balázs Gereben; Brian W Kim; Peter A Kopp; Xiao Hui Liao; Maria Jesus Obregon; Robin P Peeters; Samuel Refetoff; David S Sharlin; Warner S Simonides; Roy E Weiss; Graham R Williams
Journal:  Thyroid       Date:  2013-12-12       Impact factor: 6.568

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.